BCLI Stock Overview
A biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Brainstorm Cell Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.25 |
| 52 Week High | US$11.89 |
| 52 Week Low | US$1.05 |
| Beta | 0.39 |
| 11 Month Change | -36.21% |
| 3 Month Change | -74.30% |
| 1 Year Change | -66.45% |
| 33 Year Change | -97.77% |
| 5 Year Change | -97.90% |
| Change since IPO | -75.31% |
Recent News & Updates
Recent updates
Brainstorm Cell Therapeutics: Upcoming BLA In ALS
Aug 21BrainStorm Cell Therapeutics Q2 2022 Earnings Preview
Aug 12Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?
Aug 05
Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?
Mar 22Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?
Nov 26Brainstorm Cell Therapeutics: MSC-NTF Cell Therapy Shows Mid-Stage Promise In PMS
May 30Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Deliver On Growth Plans?
May 02BrainStorm Cell Therapeutics EPS beats by $0.07
Apr 26Who Has Been Buying Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares?
Feb 21
BrainStorm Cell Therapeutics EPS misses by $0.18
Feb 04Here's Why We're Watching Brainstorm Cell Therapeutics' (NASDAQ:BCLI) Cash Burn Situation
Jan 17BrainStorm completes dosing in Phase 2 MS Study
Dec 18BrainStorm launches NurOwn Expanded Access Program
Dec 14What Percentage Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares Do Insiders Own?
Dec 13BrainStorm's NurOwn flunks in late-stage ALS study
Nov 17Shareholder Returns
| BCLI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.3% | 2.5% | 2.2% |
| 1Y | -66.5% | 16.1% | 31.6% |
Return vs Industry: BCLI underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: BCLI underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| BCLI volatility | |
|---|---|
| BCLI Average Weekly Movement | 12.0% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BCLI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BCLI's weekly volatility has decreased from 20% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 29 | Chaim Lebovits | www.brainstorm-cell.com |
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases.
Brainstorm Cell Therapeutics Inc. Fundamentals Summary
| BCLI fundamental statistics | |
|---|---|
| Market cap | US$7.13m |
| Earnings (TTM) | -US$14.23m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs BCLI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCLI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$14.23m |
| Earnings | -US$14.23m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.49 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BCLI perform over the long term?
See historical performance and comparison